Results 171 to 180 of about 111,074 (325)

Decreased Severity of Oral Immunotherapy Induced Gastrointestinal Eosinophilic Reactions Following Revisions in Milk‐Treatment Protocol

open access: yesAllergy, EarlyView.
A revised milk OIT protocol with lower daily allergen load and slower dose escalation reduced the severity and delayed onset of OIT‐induced gastrointestinal eosinophilic reactions (OITIGER). Elevated baseline absolute eosinophil count (AEC > 600/μL) was a consistent independent risk factor for OITIGER, while older age was protective.
Na'ama Epstein‐Rigbi   +8 more
wiley   +1 more source

Evaluation of association of anti-PEG antibodies with anaphylaxis after mRNA COVID-19 vaccination

open access: hybrid, 2023
Zhao‐Hua Zhou   +25 more
openalex   +1 more source

Anaphylaxis

open access: yesEar, Nose & Throat Journal, 1996
G A, Friday, P, Fireman
openaire   +2 more sources

A case of anaphylaxis due to fish collagen in a gummy candy

open access: gold, 2019
Namiko Abe   +6 more
openalex   +1 more source

Human KIT Antibody Briquilimab Diminishes Anaphylactic Responses in Mice Expressing Chimeric Human‐Mouse KIT

open access: yes
Allergy, EarlyView.
Hye‐Sook Kwon   +14 more
wiley   +1 more source

Basophil Activation Test as Biomarker of Severity and Threshold of Allergic Reactions to Cow's Milk During Oral Food Challenges

open access: yesAllergy, EarlyView.
The threshold of reactivity during fresh milk challenges was 70% lower than that of baked milk challenges, reflecting the higher allergenicity of fresh milk. BAT was the only biomarker statistically significantly different between severity and threshold groups, for baked milk and fresh milk allergies, respectively.
Holly Boyd   +17 more
wiley   +1 more source

Cost‐Effectiveness of Venom Immunotherapy in Preventing Severe Bee and Wasp Sting Reactions

open access: yesAllergy, EarlyView.
This study evaluates the cost‐effectiveness of Hymenoptera venom depot immunotherapy (HVDI) with Alutard SQ compared to adrenaline auto‐injectors (AAIs) in Denmark. The model incorporates both psychological and physiological benefits to estimate quality‐adjusted life years (QALYs).
Gunter Sturm   +6 more
wiley   +1 more source

Long‐Term Efficacy and Safety of Ligelizumab as Re‐Treatment in Patients With Chronic Spontaneous Urticaria

open access: yesAllergy, EarlyView.
Ligelizumab re‐treatment in CSU patients showed sustained efficacy and tolerability. Over 50% achieved symptom control (UAS7 ≤ 6) by Week 12; benefits maintained through Week 52. No new safety signals observed; aligns with prior PEARL trial outcomes. CSU, chronic spontaneous urticaria; mg, milligram; q4w, every 4 weeks; UAS, urticaria activity score ...
Ana M. Gimenez‐Arnau   +22 more
wiley   +1 more source

Home - About - Disclaimer - Privacy